Skip to main content
Clinical Trials/NCT05692011
NCT05692011
Recruiting
Not Applicable

The Effects of a AN69ST Membrane and Polysulphone Membrane on Septic Children With Continuous Blood Purification

Children's Hospital of Fudan University1 site in 1 country80 target enrollmentOctober 1, 2025

Overview

Phase
Not Applicable
Intervention
blood purification(AN69ST)
Conditions
Sepsis
Sponsor
Children's Hospital of Fudan University
Enrollment
80
Locations
1
Primary Endpoint
organ injury changes
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different membrane on children with sepsis through a perspective cohort study, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.

Detailed Description

Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. Blood purification therapy is gradually developed on the basis of renal replacement therapy, and now it is more and more widely used in the field of critical care in children. CVVH can reduce the level of inflammation in the body in different membranes, but the results of reducing inflammatory factors are different, and the outcomes of patients are also different. Blood purification treatment can reduce inflammatory mediators in sepsis, but there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different blood purification membrane in children with sepsis through a perspective cohort study. Provide the corresponding basis for blood purification treatment of the disease.

Registry
clinicaltrials.gov
Start Date
October 1, 2025
End Date
December 31, 2026
Last Updated
2 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Meet the 2005 diagnostic criteria for sepsis
  • Age 29 days - 18 years old
  • Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock
  • Diagnosis \< 48 hours

Exclusion Criteria

  • Inability to obtain an informed consent from the subject, family member or an authorized surrogate
  • Subject has end-stage renal disease and requires chronic dialysis
  • There is clinical support for non-septic shock
  • Subject has had chest compressions as part of cardiopulmonary resuscitation this hospitalization without immediate return to communicative state
  • Subject has uncontrolled hemorrhage
  • Subject has immunodeficiency diseases
  • Subject has received chemoradiotherapy or immunosuppressive therapy in the 14 days before enrollment
  • HIV infection in association with a last known or suspected CD4 count of \<50/mm3
  • Subject has sustained extensive third-degree burns within the past 7 days
  • Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia

Arms & Interventions

blood purification(AN69ST)

Intervention: blood purification(AN69ST)

blood purification(PS)

Intervention: blood purification(PS)

Outcomes

Primary Outcomes

organ injury changes

Time Frame: from enrollment to the 3th days

the difference of the organ injury changes would be measured at the 3th day after enrollment

cytokine change

Time Frame: from enrollment to the 3th days

This is a binary variable. It is also a compositional variable including IL-6, IL-10, TNF-a, IL-4, IL-2 and etc. If one of the factors changes, it is considered that the variable changes. If the cytokine drops below half of the original value, it is considered to be changed. The cytokine would be measured measured at the 7th day after enrollment

Secondary Outcomes

  • survival rate(from enrollment to the 28th days)

Study Sites (1)

Loading locations...

Similar Trials